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ABSTRACT The effects of the administration of the two novel k -opioid agonists (VA-100, VA-101) on
memory processes were evaluated with the mouse passive avoidance test. The administration of VA-100
(50–100 mg kg–1 p.o.) and VA-101 (100 mg kg–1 p.o.) administered 20 min before the training session
prevented nor-binaltorphimine (4.9 m g per mouse i.c.v.), scopolamine (1.5 mg kg–1 i.p.), mecamylamine
(20 mg kg–1 i.p.), diphenhydramine (20 mg kg–1 i.p.), and baclofen (2 mg kg–1 i.p.) amnesia. At the highest
effective doses, none of the drugs impaired motor coordination, as revealed by the rota-rod test, nor modi-
fied spontaneous motility and inspection activity, as revealed by the hole board test. The antiamnesic effect
induced by VA-100 and VA-101 was comparable to that exerted by the k -opioid agonist U-50,488H, as well
as that induced by the nootropic drug piracetam and the cholinesterase inhibitor physostigmine. These
results suggest that the activation of k -opioid receptors plays an important role in the prevention of memory
impairment. On these bases, k -opioid receptor agonists could represent a useful symptomatic treatment
for cognitive deficits.  Drug Dev. Res. 54:12–18, 2001. © 2001 Wiley-Liss, Inc.
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INTRODUCTION
Opioids produce their principal effects by binding
to at least three different types of receptors, the m , d , and
k  opioid receptors [Raynor et al., 1994]. In general, the m
and d  agonists interfere with learning and memory and
produce retrograde amnesia [Castellano, 1975; Ukai et
al., 1997a]. Alternatively, the antagonists naloxone and
ICI 174,864 facilitate them, increase retention of recently
learned tasks, and alleviate amnesia [Flood et al., 1987,
Izquierdo and Netto, 1990; Schultieis and Martinez,
1990]. By contrast, activation of k -opioid receptors ap-
pears to produce opposite effects. The function of
dynorphin, an endogenous k -opioid ligand, as well as
other k -opioid agonists in the CNS has been found to
include modulation of memory processes. In particular,
activation of k -opioid receptors prevents amnesia in
laboratory animals. Dynorphin A-(1-13) and the k -opioid
agonist U-50,488H improves the scopolamine- and piren-
zepine-induced impairment of step-down type passive
avoidance response and spontaneous alternation perfor-
mance [Ukai et al., 1995, 1997b]. Dynorphin A-(1-13) also
attenuates basal forebrain-lesion-induced amnesia in rats
obtained by the injection of the cholinergic neurotoxin
ibotenic acid [Ukai et al., 1993]. Furthermore, stimula-
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tion of k -opioid receptors markedly prevents memory
dysfunctions induced by transient cerebral ischemia [Itoh
et al., 1993a,b] and improves carbon monoxide-induced
delayed amnesia in mice [Hiramatsu et al., 1995, 1996].
However, studies of the effects of k -selective agonists on
memory have yielded highly conflicting results. Izquierdo
et al. [1985] reported that posttraining administration of
dynorphin did not affect retention on either active or
passive avoidance tasks. Intracerobroventricular injec-
tion of dynorphin impairs retention of an inhibitory avoid-
ance task, but not of Y-maze discrimination [Tilson et al.,
1986; Introini-Collison et al., 1987]. Colombo et al. [1992]
reported that dynorphin A-(1-13) impaired memory in a
dose-dependent manner and that U-50,488H produced
a biphasic dose-dependent effect on cognitive function:
low doses caused a trend toward enhanced memory and
high doses caused significant impairment. Therefore, the
role of k -opioid receptor on memory processes may
depend on the concentrations and the experimental para-
digm used. VA-100 (2,3-dihydro-2-[[(4-fluorobenzoyl)-
amino]ethyl]-1-methyl-5-phenyl-1H-1,4-benzodiazepine)
and VA-101 (2,3-dihydro-2[[(2-thienylcarbonyl)amino]-
ethyl]-1-methyl-5-phenyl-1H-1,4-benzodiazepine) are
two tifluadom analogs with high affinity and selectivity
for k -opioid receptors in comparison with m  and d  recep-
tors [Cappelli et al., 1996]. By using both the above-men-
tioned k -opioid receptor agonists (VA-100 and VA-101)
and the selective antagonist nor-BNI, the role of k -opioid
receptors in the modulation of learning and memory pro-
cesses was further investigated in a passive avoidance
paradigm.
MATERIALS AND METHODS
Animals
Male Swiss albino mice (23–30 g) from Morini (San
Polo d’Enza, Italy) were used. The mice were housed 15
per cage. The cages were placed in the experimental room
24 h before the test for adaptation. The animals were fed
a standard laboratory diet and tap water ad libitum and
kept at 23 –  1 ° C with a 12-h light/dark cycle, lights on at
7 AM. All experiments were carried out according to the
guidelines of the European Community Council for ex-
perimental animal care.
Passive Avoidance Test
The test was performed according to the step-
through method described by Jarvik and Kopp [1967].
The apparatus consists of a two-compartment acrylic box
with a lighted compartment connected to a darkened one
by a guillotine door. Mice, as soon as they enter the dark
compartment, receive a punishing electrical shock (0.15
mA, 1 sec). The latency times for entering the dark com-
partment were measured in the training test and after 24
h in the retention test. For memory disruption, mice were
intraperitoneally (i.p.) injected with amnesic drugs im-
mediately after termination of the training session. VA-
100, VA-101, U-50,488H, physostigmine, and piracetam
were injected 20 min before the training session. Those
mice scoring more than 60 sec in the training session
were rejected. The maximum entry latency allowed in
the retention session was 180 sec.
Hole Board Test
The hole board test utilizes a 40-cm square plane
with 16 flush-mounted cylindrical holes (diameter 3 cm)
distributed 4 by 4 in an equidistant, grid-like manner.
The mice were placed in the center of the board one by
one and left to move about freely for a period of 5 min
each. Two photoelectric beams, crossing the plane from
mid-point to mid-point of opposite sides, thus dividing
the plane into four equal quadrants, automatically sig-
naled the movement of the animals on the surface of the
plane. Miniature photoelectric cells in each of the 16 holes
recorded the exploration of the holes (head plunging ac-
tivity) by the mice.
Rota-Rod Test
The apparatus consists of a base platform and a ro-
tating rod of 3 cm diameter with a nonskid surface. The
rod was placed at a height of 15 cm from the base. The
rod, 30 cm in length, was divided into five equal sections
by six disks. Thus, up to five mice were tested simulta-
neously on the apparatus, with a rod-rotation speed of 16
rpm. The integrity of motor coordination was assessed
on the basis of the number of falls from the rod in 30 sec,
according to Vaught et al. [1985]. Performance time was
measured before and 15, 30, and 45 min after s.c. admin-
istration of the drugs.
Intracerebroventricular Injection Technique
Intracerebroventricular (i.c.v.) administration was
performed under ether anesthesia with isotonic saline as
a solvent, according to the method described by Haley
and McCormick [1957]. During anesthesia, mice were
grasped firmly by the loose skin behind the head. A hy-
podermic needle (0.4 mm external diameter) attached to
a 10 m l syringe was inserted perpendicularly through the
skull and no more than 2 mm into the brain of the mouse,
where 5 m l of drug were then administered. The injec-
tion site was 1 mm to the right or left from the midpoint
on a line drawn through to the anterior base of the ears.
Injections were performed randomly into the right or left
ventricle. To ascertain that the drugs were administered
exactly into the cerebral ventricle, some mice were in-
jected with 5 m l of 1:10 diluted India ink and their brains
were examined macroscopically after sectioning. The
accuracy of the injection technique was evaluated, with
95% of injections being correct.
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Drugs
The following drugs were used: VA-100, VA-101
(prepared in the Dipartimento Farmaco Chimico
Tecnologico of University of Siena according to the
method described by Cappelli et al. [1996]); D-amphet-
amine (De Angeli); scopolamine hydrobromide, physos-
tigmine hemisulphate, piracetam, baclofen (Sigma, St.
Louis, MO); mecamylamine hydrochloride, U-50,488H
methane sulfonatr, nor-binaltorphimine hydrochloride
(RBI, Natick, MA).
Drugs were dissolved in isotonic (NaCl 0.9%) sa-
line solution (for i.c.v. and i.p. administration) or dispersed
in sodium carboxymethylcellulose 1% (for per os, p.o.,
administration) immediately before use. Drug concen-
trations were prepared so that the necessary dose could
be administered in a volume of 5 m l per mouse by i.c.v.
injection, and 10 ml kg–1 by i.p. and p.o. injection.
Statistical Analysis
All experimental results are given as the means –
SEM. ANOVA followed by Fisher’s Protected Least Sig-
nificant Difference (PLSD) procedure for post-hoc com-
parison was used to verify significance between two
means. Data were analyzed with the StatView software
for the Macintosh (1992). P-values < 0.05 were consid-
ered significant.
RESULTS
Amnesic Effect of k-Opioid Receptor Antagonist
The dose–response curve for n-BNI (0.049–4.9 m g
per mouse i.c.v.) in the mouse passive avoidance test is
shown in Figure 1A. The compound, injected immediately
after the training session, produced deficits in passive avoid-
ance behavior. The amnesic action was reached at the dose
of 0.49 m g. The maximum effect obtained was of the same
intensity of that produced by scopolamine (1.5 mg kg–1 i.p.)
and dicyclomine (2 mg kg–1 i.p.), used as reference drugs
(Fig. 1A). Higher doses of n-BNI were not investigated be-
cause the dose of 4.9 m g produced the same degree of be-
havioral impairment of the reference drugs (Fig. 1A).
Prevention of Deficits in Passive Avoidance
Behavior by k-Opioid Receptor Agonists
The deficits in passive avoidance behavior induced
by the k -opioid receptor antagonist n-BNI was prevented
by pretreatment with the k -opioid receptor agonists VA-
100 (50 mg kg–1 p.o.) and VA-101 (100 mg kg–1 p.o.), in-
jected 20 min before the training session. Both k -opioid
agonists enhanced the entrance latency up to a value com-
parable to that produced by control animals (Fig. 1B).
VA-100 and VA-101, at 10 and 50 mg kg–1 i.p., respec-
tively, were completely ineffective (Fig. 1B). The
antiamnesic effect of VA-100 and VA-101 was comparable
to that produced by the k -opioid receptor agonist U-
50,488H (6.0 mg kg–1 p.o.) (Fig. 1B).
VA-100 (50-100 mg kg–1 p.o.) and VA-101 (100 mg kg–1
p.o.) were also able to completely prevent scopolamine (1.5
mg kg–1 i.p.; Figs. 2, 3), mecamylamine (20 mg kg–1 i.p.; Fig.
4), diphenhydramine (20 mg kg–1 i.p.; Fig. 5), and baclofen
(2 mg kg–1 i.p.; Fig. 5) induced deficits in passive avoidance
behavior. The doses of 25 mg kg–1 p.o. for VA-100 and of 50
mg kg–1 p.o. for VA-101 were unable to protect against sco-
polamine- (Figs. 2, 3) and mecamylamine-induced (Fig. 4)
deficits in passive avoidance behavior.
The antiamnesic effect produced by VA-100 and VA-
101 was comparable to that produced by the well-known
nootropic drug piracetam (30 mg kg–1 i.p.) and the cho-
linesterase inhibitor physostigmine (0.2 mg kg–1 i.p.), as
illustrated in Figure 3.
Fig. 1. Dose–response curve of n-BNI in comparison with scopolamine
(1.5 mg kg–1 i.p.) and dicyclomine (2 mg kg–1 i.p.) in mouse passive avoid-
ance test (A) and effect on amnesia induced by n-BNI (4.9 m g per mouse
i.c.v.) of VA-100 (p.o.), VA-101 (p.o.). and U-50,488H (p.o.) (B). VA-
100, VA-101, and U-50,488H were administered 20 min before training
session while n-BNI, scopolamine, and dicyclomine were injected im-
mediately after training session. Inside the columns is the number of mice.
° P < 0.01 in comparison with saline/CMC-treated mice; ^P < 0.05; *P
< 0.01 in comparison with n-BNI-treated mice.
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Doses of VA-100 and VA-101 higher than 100 mg
kg–1 p.o. were not investigated because a complete pre-
vention of n-NBI-, scopolamine-, mecamylamine-,
diphenhydramine-, and baclofen-induced amnesia had
already been reached.
VA-100 and VA-101, when given alone, at the highest
doses used had no effect on mouse passive avoidance test
in comparison with saline-treated mice (Figs. 2, 3). No sta-
tistically significant difference among the entrance laten-
cies for each compound tested in the training session of the
passive avoidance test was observed (Figs. 1–5).
The administration schedule for VA-100 and VA-
101 was selected on the basis of results obtained from
time-course studies (data not shown).
Effect of k-Opioid Receptor Agonists and Antagonists
on Mouse Rota-Rod and Hole Board Tests
It should be noted that the k -opioid agonists and
antagonists we investigated elicited their modulatory ef-
fect on cognitive processes without changing either gross
behavior or motor coordination, as revealed by the rota-
Fig. 2. Effect of VA-100 in comparison with U-50,488H on amnesia
induced by scopolamine (1.5 mg kg–1 i.p.) in mouse passive avoidance
test. VA-100 (p.o.) and U-50,488H (p.o.) were administered 20 min be-
fore training session while scopolamine was injected immediately after
training session. Inside the columns is the number of mice. ° P < 0.01 in
comparison with CMC-treated mice. ^P < 0.05; *P < 0.01 in compari-
son with scopolamine-treated mice.
Fig. 3. Effect of VA-101 in comparison with physostigmine and piracetam
on amnesia induced by scopolamine (1.5 mg kg–1 i.p.) in mouse passive
avoidance test. VA-101 (p.o.), physostigmine (p.o.) and piracetam (p.o.)
were administered 20 min before training session while scopolamine was
injected immediately after training session. Inside the columns is the num-
ber of mice. ° P < 0.01 in comparison with CMC-treated mice. *P < 0.01
in comparison with scopolamine-treated mice.
Fig. 4. Effect of VA-100 and VA-101 on amnesia induced by mecamy-
lamine (20 mg kg–1 i.p.) in mouse passive avoidance test. VA-100 (p.o.)
and VA-101 (p.o.) were administered 20 min before training session while
mecamylamine was injected immediately after training session. Inside
the columns is the number of mice. ° P < 0.01 in comparison with CMC-
treated mice. *P < 0.01 in comparison with mecamylamine-treated mice.
Fig. 5. Effect of VA-100 and V A-101 on amnesia induced by diphen-
hydramine (20 mg kg–1 i.p.) and baclofen (2 mg kg–1 i.p.) in mouse pas-
sive avoidance test. VA-100 and VA-101 were administered 20 min before
training session, diphenhydramine and baclofen were injected immedi-
ately after training session. Inside the columns is the number of mice. ° P
< 0.01 in comparison with CMC-treated mice. ^ P < 0.05; *P < 0.01 in
comparison with diphenhydramine or baclofen-treated mice.
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rod test (Table 1). None of the drugs, administered at the
highest active doses, increased the number of falls from
the rotating rod in comparison with saline-treated mice
(Table 1). The number of falls in the rota-rod test pro-
gressively decreased since mice learned how to balance
on the rotating rod.
The spontaneous motility and inspection activity
of mice was unmodified by administration of the k -opioid
agonists VA-100 and VA-101 and of the k -opioid antago-
nist n-BNI, as revealed by the hole board (Fig. 6) test in
comparison with saline-treated mice. In this, test D-am-
phetamine (2 mg kg–1 i.p.), used as a reference drug, in-
creased both parameters evaluated.
DISCUSSION
The present results demonstrate that the adminis-
tration of the k -opioid receptor antagonist n-BNI pro-
vokes amnesia in the mouse passive avoidance test of a
severity comparable to that induced by the amnesic drugs
scopolamine and dicyclomine. This amnesic effect was
centrally mediated, since it was obtained after intracere-
broventricular administration.
The amnesia induced by n-BNI was prevented by
the k -opioid receptor agonists VA-100, VA-101, and U-
50,488H, indicating the important role played by the k -
opioid receptors in modulating learning and memory
processes. The blockade of these opioid receptors im-
pair cognitive functions that are, by contrast, improved
by stimulation of k  receptors. VA-100 and VA-101 exerted
an antiamnesic action of an efficacy comparable to that
shown by the well-known k -opioid agonist U-50,488H,
even if the potency of the two compounds is lower than
that detected for U-50,488H. However, VA-100 and VA-
101 can represent a useful pharmacological tool to inves-
tigate the physiological role of k -opioid receptors.
VA-100 and VA-101, as well as U-50,488H, are also
able to prevent amnesia induced by the antimuscarinic drug
scopolamine, with a procognitive effect similar to that ex-
erted by the cholinesterase inhibitor physostigmine and the
nootropic drug piracetam. This experimental results are in
agreement with previous data reporting that dynorphin A-
(1-13) ameliorates the scopolamine- and pirenzepine-in-
duced memory impairment of step-down type passive
avoidance response and spontaneous alternation perfor-
mance [Ukai et al., 1997b]. Furthermore, it has been re-
ported that the k -opioid agonist U-50,488H improves
scopolamine- and pirenzepine-induced memory impair-
ment in mice and rats [Ukai et al., 1995; Hiramatsu et al.,
1998]. Dynorphin A-(1-13) is also able to protect against
amnesia induced by hypofunctionality of the cholinergic
system not related to an antagonism of the muscarinic re-
ceptors. Dynorphin A-(1-13) attenuates basal forebrain-le-
sion-induced amnesia in rats obtained by the injection of
the cholinergic neurotoxin ibotenic acid [Ukai et al., 1993]
and b -amyloid peptide (25-35)-amnesia in a mouse passive
avoidance paradigm [Hiramatsu et al.,2000]. Dynorphin A-
(1-13) also prevents amnesia in mice induced by galanin
[Kameyama et al., 1994], an ACh releaser inhibitor [Fisone
et al., 1987], and by cycloheximide [Ukai et al., 1996], a
protein synthesis inhibitor endowed with amnesic proper-
ties mainly due to an impairment of the neuronal cholin-
ergic system [Nabeshima et al., 1988].
VA-100 and VA-101 prevented amnesia induced by
the nicotinic antagonist mecamylamine. The observation
that the k -opioid agonist U-50,488H improves mecamy-
lamine-induced memory impairment in mice and rats
[Ukai et al., 1995; Hiramatsu et al., 1998] confirmed our
results. However, mecamylamine amnesia underlies an
impairment of the cholinergic system. It has been re-
ported that nicotine enhances cholinergic transmission
through the activation of presynaptic nicotinic receptors
[McGehee et al., 1995], whereas mecamylamine signifi-
cantly decreases the release of ACh from rat hippocam-
pus revealed by a microdialysis technique [Hiramatsu et
al., 1998]. Taking into account these observations, the
prevention exerted by k -opioid agonists of memory defi-
cits induced by nicotinic antagonists is also related to an
antimuscarinic mechanism.
TABLE 1. Effect of nor-Binaltorphimine, VA-100, VA-101, and U-50,448H in Mouse Rota Rod Test
Falls in 30 sec
After treatment
Treatment Dose Before treatment 15 min 30 min 45 min
Saline 5 m l icv 3.7 ± 0.6 2.5 ± 0.3 1.8 ± 0.4 1.4 ± 0.3
CMC 10 ml kg–1 po 3.8 ± 0.4 2.0 ± 0.2 1.8 ± 0.3 0.8 ± 0.2
nBNI 4.9 m g icv 3.9 ± 0.4 2.6 ± 0.4 1.5 ± 0.2 0.6 ± 0.2
U-50,488H 6 mg kg–1 po 4.0 ± 0.4 2.5 ± 0.4 1.9 ± 0.3 0.7 ± 0.2
VA-100 100 mg kg–1 po 3.6 ± 0.5 2.2 ± 0.4 1.5 ± 0.3 1.1 ± 0.3
VA-100 200 mg kg–1 po 3.8 ± 0.4 4.4 ± 0.5* 3.6 ± 0.4* 2.6 ± 0.4*
VA-101 100 mg kg–1 po 3.5 ± 0.4 2.4 ± 0.3 1.1 ± 0.3 1.0 ± 0.2
VA-101 200 mg kg–1 po 3.9 ± 0.3 4.1 ± 0.5* 3.8 ± 0.3* 3.1 ± 0.4*
*P < 0.01 in comparison with saline or CMC controls. Each value represents the mean of five mice.
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VA-100 and VA-101 prevented amnesia induced by
administration of the GABAB agonist baclofen and the
H1-antagonist diphenhydramine, indicating that k -opioid
receptor agonists were able to prevent amnesia induced
not only by antimuscarinic drugs, but also through a
mechanism that does not involve the blockade of the cho-
linergic system. The antagonist of a GABAB-mediated
effect by k -opioid agonists is confirmed by previous re-
sults reporting that k -opioid receptor activation inhib-
ited GABAB-mediated IPSPs in the guinea pig ventral
tegmental area [Shoji et al., 1999]. Furthermore, baclofen,
at low i.c.v. doses unable to induce antinociception, at-
tenuated the increase of the pain threshold induced by
U-50,488H [Suh et al., 1995]. The prevention of U-
50,488H antinociception by the H1-antagonist cyprohep-
tadine in the rat tail flick test [Suh et al., 1999] supported
the hypothesis of a possible correlation between activa-
tion of k -opioid receptors and antagonism of H1 recep-
tors suggested by our results on passive avoidance.
The experimental data obtained by the use of two
new and selective k -opioid agonists VA-100 and VA-101,
indicate that activation of k -opioid receptors improves
pharmacologically induced cognitive deficits.
The k -opioid receptor agonists and antagonists, at
the highest doses used, did not modify the animals’ gross
behavior. Nor did these compounds impair motor coor-
dination, as revealed by the rota-rod test, or modify loco-
motor and inspection activity, as indicated by the hole
board test. We can thus suppose that the effects produced
by k -opioid receptor modulators were not imputable to
compromised viability. Higher doses of all compounds
were not investigated since the maximum amnesic (n-
BNI) and antiamnesic (VA-100, VA-101) effect was already
reached.
In conclusion, these results confirm the important
role played by k -opioid receptors in the regulation of
memory processes. On these bases, the k -opioid recep-
tor agonists could be useful in the treatment of cognitive
deficits while k -opioid receptor antagonists may repre-
sent pharmacological tools for investigation of new po-
tential antiamnesic drugs.
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